Business
SANUWAVE Health Announces Reimbursement Coverage for BIOVANCE from Largest Medicare and Medicaid Administrator in U.S.
24.5 Million Covered Lives Now Eligible for Biologic Advanced Wound Care Treatment through Centene Corporation SUWANEE, GA, Sept. 08, 2020 (GLOBE NEWSWIRE) --
About this update from Sanuwave Health, Inc.
[{"type":"text","content":"24.5 Million Covered Lives Now Eligible for Biologic Advanced Wound Care Treatment through Centene Corporation\n SUWANEE, GA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV), whose focus is the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin, musculoskeletal tissue and vascular structures, announced today that Centene Corporation, the largest Medicare and Medicaid Administrator in the U.S., has included SANUWAVE’s BIOVANCE® in its list of reimbursed skin substitutes for advanced wound healing for the more than 24.5 million lives it covers. BIOVANCE is decellularized, dehydrated human amniotic membrane (DDHAM) that is an intact, natural extracellular matrix (ECM) that acts as a scaffold for restoration of functional tissue. BIOVANCE contains key ECM proteins that allow for the migration of host cells to permeate the graft and promote tissue repair when applied to a wound. BIOVANCE brings the progenerative power of the amnion to tissue regeneration1-6 and provides a foundation for the wound healing process. “Inclusion in Centene’s list of reimbursable skin substitutes for advanced wound healing products is a key milestone for BIOVANCE as we continue to expand our Medicare and Medicaid access to benefit the millions of elderly patients suffering with recalcitrant wounds,” said Ryan K. Sheffer, Senior Director Reimbursement & Health Policy for SANUWAVE Health. “Moving forward, we expect to increase our coverage from national payors with a goal to gain access to the more than 250 million commercial and managed Medicare patients, which is expected to drive BIOVANCE revenue and grow SANUWAVE’s share in the multi-billion dollar advanced wound care market.” About Centene Corporation Centene Corporation, a Fortune 100 company, is a leading multi-national healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and ...